Company profile for Galenicum

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Galenicum is dedicated to the development, production and registration of finished pharmaceutical products and to sales of active ingredients. A company with a global vision, Galenicum is headquartered in Barcelona, Spain, and has an office in Madrid. Galenicum's international offices are located in Brazil, Chile, India, Malta and Peru.Life is about overcoming, and so is the pharmaceutical industry.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Spain
Address
Address
Avenida Diagonal 123, 11th Floor08005 Barcelona - Spain
Telephone
Telephone
34 932 011 750
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

BioProcess International US West

Not Confirmed

envelop Contact Supplier

BioProcess International US West

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.lupin.com/lupin-and-galenicum-sign-license-and-supply-agreement-for-semaglutide-in-23-countries/

PRESS RELEASE
22 Jan 2026

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216422

FDA
19 May 2025

http://twofourinsight.com/grunenthal-denied-indian-patent-use-tapentadol-treat-osteoarthritis-pain/

TWOFOUR INSIGHT
27 Jan 2016

Drugs in Development

read-more
read-more

Details:

Through the licensing deal for Semaglutide, a peptide targeting the GLP-1 receptor, the agreement aims to advance treatments for type 2 diabetes.


Lead Product(s): Semaglutide

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Peptide, Unconjugated

Sponsor: Lupin Ltd

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 21, 2026

blank

01

Galenicum

Spain
arrow
BioProcess International US West
Not Confirmed

Galenicum

Spain
arrow
BioProcess International US West
Not Confirmed

Details : Through the licensing deal for Semaglutide, a peptide targeting the GLP-1 receptor, the agreement aims to advance treatments for type 2 diabetes.

Product Name : Undisclosed

Product Type : Peptide, Unconjugated

Upfront Cash : Undisclosed

January 21, 2026

blank

Details:

Sitagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.


Lead Product(s): Sitagliptin Phosphate,Metformin

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 09, 2023

blank

02

Galenicum

Spain
arrow
BioProcess International US West
Not Confirmed

Galenicum

Spain
arrow
BioProcess International US West
Not Confirmed

Details : Sitagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 09, 2023

blank

Details:

Sitagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.


Lead Product(s): Sitagliptin Phosphate,Metformin

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 09, 2023

blank

03

Galenicum

Spain
arrow
BioProcess International US West
Not Confirmed

Galenicum

Spain
arrow
BioProcess International US West
Not Confirmed

Details : Sitagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 09, 2023

blank

Details:

Sitagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.


Lead Product(s): Sitagliptin Phosphate,Metformin

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 09, 2023

blank

04

Galenicum

Spain
arrow
BioProcess International US West
Not Confirmed

Galenicum

Spain
arrow
BioProcess International US West
Not Confirmed

Details : Sitagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 09, 2023

blank

Details:

Sitagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.


Lead Product(s): Sitagliptin Phosphate,Metformin

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 09, 2023

blank

05

Galenicum

Spain
arrow
BioProcess International US West
Not Confirmed

Galenicum

Spain
arrow
BioProcess International US West
Not Confirmed

Details : Sitagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 09, 2023

blank

Details:

Sitagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.


Lead Product(s): Sitagliptin Phosphate,Metformin

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 22, 2022

blank

06

Galenicum

Spain
arrow
BioProcess International US West
Not Confirmed

Galenicum

Spain
arrow
BioProcess International US West
Not Confirmed

Details : Sitagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 22, 2022

blank

Details:

Sitagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.


Lead Product(s): Sitagliptin Phosphate,Metformin

Therapeutic Area: Endocrinology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 22, 2022

blank

07

Galenicum

Spain
arrow
BioProcess International US West
Not Confirmed

Galenicum

Spain
arrow
BioProcess International US West
Not Confirmed

Details : Sitagliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 22, 2022

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Inspections and registrations

Upload your audits for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty